Jiabiyou's 6th Anniversary on the STAR Market: Long-termism Forges a New Benchmark in Bio-manufacturing
Wuhan, December 19, 2025 /PRNewswire/ -- Recently, JBT celebrated the important milestone of its sixth anniversary since listing. On December 19, 2019, JBT became the first company in China's food biotechnology sector to list on the STAR Market. Six years later, this innovative company from Wuhan's Optics Valley has demonstrated the profound value of long-termism through sustained performance breakthroughs and strategic positioning.
JBT's STAR Market listing ceremony, 2019
- Performance Leap: Steady Growth from 300M to 550M
Over six years post-listing, JBT has charted a high-quality growth trajectory. Revenue climbed steadily from RMB 312 million in 2019 to RMB 555 million in 2024, with a CAGR of 12.2%; net profit increased from RMB 96 million to RMB 124 million. Growth accelerated further in 2025, with Q1-Q3 revenue reaching RMB 428 million and net profit attributable to shareholders hitting RMB 129 million, up 54.18% YoY, surpassing last year's total.
This performance is underpinned by a robust product matrix. JBT's core product ARA has seen rising global market share; algal DHA sales exceeded RMB 100 million; 114 SA products have received regulatory approval, leading industry production capacity; HMO 2'-FL achieved ton-scale production, significantly filling China's HMO market gap and advancing domestic bio-manufacturing in food and related sectors. These high-value nutrients form a "one core, two wings" business system covering human nutrition, animal nutrition, and personal care, cementing the company's irreplaceable role in global supply chains.
Wuhan Synthetic Biology Innovation Center
- Tech Deep Dive: R&D Investments Bear Fruit
Sustained high R&D investment is JBT's foundational strategy. 2024 R&D spending reached RMB 47.9071 million (8.6% of revenue), with RMB 119 million cumulatively over three years. The company has built six core capabilities including high-throughput screening, high-density fermentation, and enzyme rational design, integrating AI to create an intelligent R&D platform that closes the loop from "0 to 1" innovation to "1 to 100" industrialization.
This system has overcome key challenges like microbial fermentation for SA (>98% purity) and DHA algal oil stability control, with multiple technical indicators reaching international advanced levels. Crucially, JBT achieved full-chain autonomy from strain design to fermentation, purification, and microencapsulation, breaking foreign monopolies in industrial strains and high-end enzymes while ensuring stable supply under extreme conditions.
- Strategic Positioning: Joining National Bio-Manufacturing Team
JBT's rise coincides with China's bio-manufacturing strategic upgrade. As the 15th Five-Year Plan prioritizes bio-manufacturing for economic growth, JBT's foresight has created a "trinity" advantage across policy, technology, and industry dimensions.
Policy-wise, JBT aligned with national directives, participating in MIIT's first "Bio-Manufacturing Flagship Products" selection (2'-FL made the list), joining the "Bio-Manufacturing Pilot Platform" initiative, and leading the "High-Performance Bioreactor" project. Chairman Yi Dewei contributed to MIIT's SME roundtable, marking JBT's deep integration into China's innovation system as a key bio-economy node.
Industrially, JBT operates three international-standard production bases with FDA GRAS, EU Novel Food, and FSSC22000 certifications. Overseas business spans 30+ countries/regions, with long-term partnerships with Nestlé, Danone, and Cargill, transitioning from ingredient supplier to platform enterprise.
- Ecosystem: From Company to Industrial Cluster
As Hubei's first STAR Market company, JBT drives regional industrial upgrading. Its RMB 300 million Wuhan Synthetic Biology Innovation Center creates a 70,000㎡ digital hub with "government-industry-academia-research-application-finance" collaboration, attracting upstream/downstream firms to Optics Valley for a complete industrial chain.
In November, JBT joined China's Synthetic Biology Standardization Project, leading multiple national/industry standards. This shift from innovation to standard-setting gives JBT rule-making authority in the trillion-yuan bio-manufacturing sector.
- 15th Five-Year Plan: Full-Stack Platform Ready
At the 14th/15th Five-Year Plan transition, JBT focuses on three areas:
Tech: Core Equipment Localization & Advanced Molecules
While developing parallel bioreactors, JBT advances harder-to-make HMOs (3-FL, 6'-SL) and expands into recombinant collagen and vaccine adjuvants via its cell factory/fermentation platforms, evolving from nutrient supplier to full-stack "tools-core ingredients-solutions" provider.
Industry: Pilot Platform Expansion
Per MIIT's Bio-Manufacturing Pilot Platform Guidelines, JBT built an open platform for strain validation, process scaling, and quality control, serving its pipeline while opening to universities, institutes, and SMEs to bridge "paper-to-product, sample-to-commodity" gaps. Phase II of its Wuhan plant adds 500-ton microbial oil capacity, with flexible production for "small-batch, multi-category, fast-response" manufacturing.
Ecosystem: Win-Win Industrial Chain
Via its Innovation Center, JBT collaborates with local governments, testing agencies, and investors for a "R&D-pilot-standards-market access-capital" service system, creating a bio-manufacturing public service nexus to accelerate regional clusters.
Epilogue: Six Years, An Era's Microcosm
From China's first ARA production line (2004) to STAR Market debut (2019) to current national bio-manufacturing flagship status, JBT's 21-year tech focus and 6-year capital empowerment completed its leap from "first stock" to "national team."
This reflects not just revenue/capacity growth but paradigm shifts in tech, industrial positioning, and global influence. As China's bio-manufacturing progresses from "following" to "leading," JBT proves true innovation lies not in trends but frontier perseverance; true value not in short-term returns but long-term commitment.
Six years ago, JBT entered public view as a STAR Market pioneer; today, it's a steady yet dynamic bio-manufacturing leader. With policy tailwinds, tech breakthroughs, and industrial synergy, JBT will not only lead China's bio-manufacturing into high-quality development but carve an irreplaceable Eastern mark on the global bio-economy map.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
